Liquefied Natural Gas Ltd
.png)
LNG Details
-
Oil & gas prices recovery drove the stock higher: The shares of Liquefied Natural Gas Ltd (ASX: LNG) rallied over 13.1% on June 07, 2016 leading to a total rally of over 22.88% in the last five days alone. The strong recovery in the oil prices contributed to the growth in the stock even though there is no news from the company. Despite this rally we remain bullish on the stock given its marketing efforts for progressing its Magnolia LNG’s offtake capacity via financing and into construction, finalizing Bear Head LNG regulatory process, and the marketing of liquefaction tolling capacity. The group is focusing on midscale LNG export projects, via its patented OSMR® liquefaction process technology, and positioning for long-term success.
-
Recommendation: We give a “Buy” recommendation on the stock at the current price of $1.005
Santos Ltd
.png)
STO Details
-
Solid LNG portfolio: Santos Ltd (ASX: STO) stock rallied over 4.1% on June 07, 2016 driven by the recovering oil and gas prices despite there is no update from the firm. On 26 May 2016, the group reported that its GLNG train 2 has started producing liquefied natural gas (LNG) in Curtis Island, Queensland. GLNG project has already delivered around two million tonnes of LNG and shipped 32 cargoes. This GLNG train 2 would further drive the group’s LNG performance apart from Darwin LNG and PNG LNG projects. The second well of the group’s five-well development campaign at Tirrawarra – Gooranie Field was also recently spudded.
-
Recommendation: Given the recovering oil prices coupled with solid LNG portfolio, we give a “Buy” recommendation on this dividend yield stock at the current price of $4.71
.png)
Tirrawarradrilling report (Source: Company reports)
Mayne Pharma Group Ltd
.png)
MYX Details
-
Received approval for dofetilide capsules: Mayne Pharma Group Ltd (ASX: MYX) stock surged over 2.24% on June 07, 2016 as the group received the US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for dofetilide capsules (125 mcg, 250mcg and 500 mcg) in the United States. The group is starting the commercial launch. This is the first generic alternative to Tikosyn® in the US, and management believes that this life-saving drug is very affordable to patients. The group built >35 generic and branded drug products in development and is aiming US markets with IMS sales >US$6.5 billion. MYX intends to make more product launches in the next year and has 12 drug applications pending at the FDA. On the other hand, the shares of MYX have already rallied over 47.6% (as of June 06, 2016) in the last one year placing the stock at relatively unreasonable valuations. MYX is also trading at a very high P/E.
-
Recommendation: We give an “Expensive” recommendation on the stock at the current price of $1.61
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.